A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Medical Device Maker Ambu Launches New Single-Use Cystoscope for Improved Workflow and Enhanced Productivity Benefits

Ambu Inc., a rapidly growing medical device maker and pioneer of sterile, single-use endoscopes, introduced today a new single-use cystoscope.

The Ambu aScope™ 4 Cysto will give urologists immediate access to a single-use cystoscope that can be used for procedures such as bladder cancer surveillance, stent removal and other common cystoscopy procedures.

Built on more than 10 years of single-use endoscopy experience, the launch of the aScope 4 Cysto enables Ambu to enter a large new market segment. Its new cystoscope will provide urologists a way to better manage their schedules and be more productive without worrying about device deterioration and other issues such as availability, reprocessing and costly repairs.

“This is a game changer,” said Juan Jose Gonzalez, CEO of Ambu S/A, headquartered in Ballerup, Denmark. “Urologists will now have immediate access to a high-quality scope that eliminates reprocessing and repairs. A urologist opens the package and immediately has a new scope offering peak performance with full articulation. They don’t have to wait and worry whether a scope will be available or whether it will work properly.”

The aScope 4 Cysto enables organizations to reduce costs on cleaning supplies, maintenance and repairs (and the associated long-term service contracts). It improves workflow and is portable, which makes it easier for doctors to deal with in-house consult procedures.

“The Cystoscope is a multi-purpose tool used by all urologists; therefore, we are excited to introduce the aScope 4 Cysto which affords urologists excellent imaging, smooth maneuverability, and consistent performance every time,” said Jens Kemp, Ambu Inc.’s vice president of U.S. marketing.  “It is a perfect solution for both flexible cystoscopies performed in the outpatient clinic as well as inpatient consults on the ward and ER. “

aView 2 Advance

Ambu, already the world leader in single-use scopes, is ramping up manufacturing to provide a single-use endoscope solution in multiple flexible endoscopy segments, including Pulmonology, ENT, Urology and Gastroenterology. In conjunction with the aScope 4 Cysto and additional endoscopes coming to market, Ambu also recently introduced  its aView™ 2 Advance, a state-of-the-art, high-definition monitor. This mobile platform can be used by pulmonologists, ENTs, urologists, thoracic surgeons, intensive care specialists and other specialists who perform millions of endoscopy procedures each year.

Ambu launched the world’s first single-use flexible bronchoscope, the Ambu® aScope™ in 2009. Ten years later, in 2019, over 600,000 Ambu single-use endoscopes were used in more than 3,500 hospitals making Ambu the world’s largest supplier of single-use endoscopes. The aScope Cysto builds on this history of innovation and close collaboration with healthcare professionals.

SourceAmbu
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy